EW - Edwards Lifesciences Non-GAAP EPS of $0.64 beats by $0.03 revenue of $1.35B beats by $20M

• Edwards Lifesciences press release ( NYSE: EW ): Q4 Non-GAAP EPS of $0.64 beats by $0.03 .
• Revenue of $1.35B (+1.5% Y/Y) beats by $20M .
• Shares +2.3% .
• Q4 TAVR sales were flat; constant currency sales grew 5 percent
• Overall, the company is reaffirming the sales guidance it provided at the December investor conference for all product groups.  Full year 2023 sales are expected to grow 9 to 12 percent to $5.6 to $6.0 billion.  Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.45 to $2.60 vs.  $2.50 consensus
• For the first quarter of 2023, the company projects total sales to be between $1.37 and $1.45 billion, and adjusted EPS of $0.58 to $0.64.

For further details see: